CN101977620B - 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物 - Google Patents

用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物 Download PDF

Info

Publication number
CN101977620B
CN101977620B CN200980110610.4A CN200980110610A CN101977620B CN 101977620 B CN101977620 B CN 101977620B CN 200980110610 A CN200980110610 A CN 200980110610A CN 101977620 B CN101977620 B CN 101977620B
Authority
CN
China
Prior art keywords
cyclopenta
cells
folate
quinazoline
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980110610.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101977620A (zh
Inventor
G·詹森
A·杰克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0805035A external-priority patent/GB0805035D0/en
Priority claimed from GB0805036A external-priority patent/GB0805036D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of CN101977620A publication Critical patent/CN101977620A/zh
Application granted granted Critical
Publication of CN101977620B publication Critical patent/CN101977620B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN200980110610.4A 2008-03-18 2009-03-13 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物 Active CN101977620B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0805035A GB0805035D0 (en) 2008-03-18 2008-03-18 Us eof cyclopenta[G]quinazoline derivatives
GB0805036.1 2008-03-18
GB0805036A GB0805036D0 (en) 2008-03-18 2008-03-18 New use of cyclopenta[g]quinazoline derivatives
GB0805035.3 2008-03-18
PCT/GB2009/000687 WO2009115776A1 (en) 2008-03-18 2009-03-13 Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia

Publications (2)

Publication Number Publication Date
CN101977620A CN101977620A (zh) 2011-02-16
CN101977620B true CN101977620B (zh) 2014-05-07

Family

ID=40599662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980110610.4A Active CN101977620B (zh) 2008-03-18 2009-03-13 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物

Country Status (10)

Country Link
US (1) US8466111B2 (cg-RX-API-DMAC7.html)
EP (1) EP2293807B1 (cg-RX-API-DMAC7.html)
JP (1) JP5599773B2 (cg-RX-API-DMAC7.html)
KR (1) KR101616022B1 (cg-RX-API-DMAC7.html)
CN (1) CN101977620B (cg-RX-API-DMAC7.html)
AT (1) ATE556715T1 (cg-RX-API-DMAC7.html)
CA (1) CA2717954C (cg-RX-API-DMAC7.html)
DK (1) DK2293807T3 (cg-RX-API-DMAC7.html)
ES (1) ES2387334T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009115776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819510A1 (en) * 2010-12-22 2012-06-28 Onyx Pharmaceuticals, Inc. Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta(g)quinazoline trisodium salt
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
KR102584446B1 (ko) 2016-08-12 2023-10-04 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도
GB201707864D0 (en) 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
WO2019157146A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
JP7514533B2 (ja) 2018-02-07 2024-07-11 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12246018B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
US12290518B2 (en) 2018-02-14 2025-05-06 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
US12048767B2 (en) * 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
JP7442822B2 (ja) 2018-02-14 2024-03-05 エル．イー．エー．エフ． ホールディングス グループ エルエルシー γポリグルタミン酸化テトラヒドロ葉酸およびその使用
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
WO2019169029A1 (en) * 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Target specific chemotherapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020748A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Anti-cancer cyclopenta[g]quinazoline compounds
WO2003020300A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
WO2003072091A1 (en) * 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020748A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Anti-cancer cyclopenta[g]quinazoline compounds
WO2003020300A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
WO2003072091A1 (en) * 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antifolates targeted specifically to the folate receptor;Jackman A L et al;《Advanced drug delivery reviews》;20040429;第56卷(第8期);1111-1125 *
BGC 945,a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors;Gibbs D et al;《Cancer research》;20051215;第64卷(第24期);11721-11728 *
Targeting the alpha-folate receptor with cyclopenta(g)quinazoline-based inhibitors of thymidylate synthase;Henderson E A et al;《Bioorganic and medicinal chemistry》;20060715;第14卷(第14期);5020-5042 *

Also Published As

Publication number Publication date
WO2009115776A1 (en) 2009-09-24
US20110190211A1 (en) 2011-08-04
EP2293807B1 (en) 2012-05-09
CA2717954A1 (en) 2009-09-24
KR20110002848A (ko) 2011-01-10
US8466111B2 (en) 2013-06-18
JP2011515384A (ja) 2011-05-19
ATE556715T1 (de) 2012-05-15
CN101977620A (zh) 2011-02-16
JP5599773B2 (ja) 2014-10-01
HK1154786A1 (en) 2012-05-04
CA2717954C (en) 2019-06-04
KR101616022B1 (ko) 2016-04-28
ES2387334T3 (es) 2012-09-20
EP2293807A1 (en) 2011-03-16
DK2293807T3 (da) 2012-07-23

Similar Documents

Publication Publication Date Title
EP2293807B1 (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
Van Der Heijden et al. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
CN111655726B (zh) 抗叶酸受体α抗体偶联物和其用途
Hooijberg et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
CN104174025B (zh) Sparc结合肽及其应用
CN105198997B (zh) Cd37免疫治疗剂及其与双功能化学治疗剂的联合
US20030148955A1 (en) Soluble tumor necrosis factor receptor treatment of medical disorders
TWI620565B (zh) 治療及預防移植物抗宿主病之方法
US9474757B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
US20010021380A1 (en) Soluble tumor necrosis factor receptor treatment of medical disorders
US20200030442A1 (en) Combination therapies
BRPI0719109A2 (pt) Métodos para tratar doenças inflamatórias crônicas usando um antagonista de gm-csf
CN111329989A (zh) Tec家族激酶抑制剂辅助疗法
JP2024038132A (ja) 神経内分泌腫瘍の処置の方法
ES2696348T3 (es) Anticuerpos anti CD84, composiciones que comprenden los mismos y usos de los mismos
TWI728400B (zh) Cd226促效劑抗體
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
JPWO2012111790A1 (ja) 化学療法剤の抗腫瘍活性増強剤
WO2005016241A2 (en) Synthetic chemokine receptor ligands and methods of use thereof
CN105873950A (zh) 用于治疗和诊断癌症的抗s100a7抗体
US8940701B2 (en) Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
CN117062842A (zh) 新型双环肽
EP3815709A1 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
US20190216923A1 (en) Methods and combination therapy to treat cancer
HK1154786B (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant